CORT - Corcept Therapeutics Incorporated
| Previous Close | 10.65 |
| Open | 10.65 |
| Bid | 0.00 x 1200 |
| Ask | 0.00 x 1400 |
| Day's Range | 10.55 - 10.80 |
| 52 Week Range | 9.14 - 19.48 |
| Volume | 309,228 |
| Avg. Volume | 678,969 |
| Market Cap | 1.231B |
| Beta (3Y Monthly) | 1.54 |
| PE Ratio (TTM) | 17.57 |
| EPS (TTM) | 0.61 |
| Earnings Date | Aug 7, 2019 - Aug 12, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.50 |
- Simply Wall St.•8 days ago
Can We See Significant Insider Ownership On The Corcept Therapeutics Incorporated (NASDAQ:CORT) Share Register?
If you want to know who really controls Corcept Therapeutics Incorporated (NASDAQ:CORT), then you'll have to look at...
- Simply Wall St.•28 days ago
Corcept Therapeutics Incorporated (NASDAQ:CORT): Poised For Long Term Success?
Looking at Corcept Therapeutics Incorporated's (NASDAQ:CORT) earnings update in March 2019, the consensus outlook from...
- Zacks•last month
Corcept (CORT) Down 11.3% Since Last Earnings Report: Can It Rebound?
Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Benzinga•2 months ago
The Week Ahead In Biotech: ASCO Presentations Pick Up The Pace
Biotech stocks came under pressure this week ahead of the ASCO 2019 presentations. Headlines on legal woes related to the opioid crisis and drug price manipulation led to weakness in some stocks. The unfolding ...
- Simply Wall St.•2 months ago
Is Corcept Therapeutics Incorporated's (NASDAQ:CORT) P/E Ratio Really That Good?
This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios...
- GlobeNewswire•2 months ago
Corcept Therapeutics to Present Data from Phase 1/2 Trial of Relacorilant Plus Nab-Paclitaxel in Patients with Solid Tumors at the American Society of Clinical Oncology Annual Meeting
Corcept Therapeutics Incorporated (CORT), a commercial-stage company engaged in the discovery and development of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, will present data from the Phase 1/2 study of its proprietary, selective cortisol modulator, relacorilant, in combination with nab-paclitaxel (Abraxane®) in patients with solid tumors, at the 2019 annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois (May 31 – June 4). “Encouraging results in patients with platinum-resistant ovarian cancer prompted us, after consultation with our investigators, to initiate a 180-patient, controlled Phase 2 trial of relacorilant plus nab-paclitaxel in that indication earlier this year.
- ACCESSWIRE•2 months ago
Lawsuit for Investors in shares of Corcept Therapeutics Incorporated (NASDAQ: CORT) announced by Shareholders Foundation
SAN DIEGO, CA / ACCESSWIRE / May 20, 2019 / The Shareholders Foundation, Inc. announces that a lawsuit was filed for certain investors in Corcept Therapeutics Incorporated (NASDAQ: CORT) shares. Investors, ...
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of CORT earnings conference call or presentation 9-May-19 9:00pm GMT
Q1 2019 Corcept Therapeutics Inc Earnings Call
- GlobeNewswire•2 months ago
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Corcept, Mobile TeleSystems, Healthcare Services, and American Renal and Encourages Investors to Contact the Firm
NEW YORK, May 16, 2019 -- Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Corcept Therapeutics.
- GlobeNewswire•2 months ago
CRBP, NIO & CORT Deadline Alert - Bronstein, Gewirtz & Grossman, LLC Class Action
NEW YORK, May 13, 2019 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following.
- Business Wire•2 months ago
DEADLINE MONDAY REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Corcept Therapeutics Incorporated and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Corcept Therapeutics Incorporated (“Corcept” or “the Company”) (NASDAQ: CORT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- GlobeNewswire•2 months ago
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of CORT, HCSG, BA and NOK
NEW YORK, May 13, 2019 -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss.
- GlobeNewswire•2 months ago
DEADLINE TODAY: Rosen Law Firm Reminds Corcept Therapeutics Incorporated Investors of Important May 13th Deadline in Securities Class Action Lawsuit - CORT
NEW YORK, May 13, 2019 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Corcept Therapeutics Incorporated (NASDAQ: CORT) from.
- GlobeNewswire•2 months ago
INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In NIO, CORT, HCSG or FCHS To Contact The Firm
NEW YORK, May 12, 2019 -- Faruqi & Faruqi, LLP, a leading national securities law firm, encourages investors in the following companies to contact the firm: Company:.
- ACCESSWIRE•2 months ago
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of CORT, FSNN and BSX
NEW YORK, NY / ACCESSWIRE / May 10, 2019 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have ...
- ACCESSWIRE•2 months ago
3-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Corcept Therapeutics Incorporated and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / May 10, 2019 / The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Corcept Therapeutics Incorporated ...
- ACCESSWIRE•2 months ago
CLASS ACTION UPDATE for CORT, FSNN and MWA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
NEW YORK, NY / ACCESSWIRE / May 10, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested ...
- GlobeNewswire•2 months ago
DEADLINE MONDAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Corcept Therapeutics Incorporated and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Corcept Therapeutics Incorporated (“Corcept” or “the Company”) (NASDAQ: CORT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.
Motley Fool•2 months agoCorcept Therapeutics Incorporated (CORT) Q1 2019 Earnings Call Transcript
CORT earnings call for the period ending March 31, 2019.
- Zacks•2 months ago
Corcept Therapeutics (CORT) Q1 Earnings Top Estimates
Corcept (CORT) delivered earnings and revenue surprises of 11.11% and -3.96%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•2 months ago
Corcept: 1Q Earnings Snapshot
The Menlo Park, California-based company said it had net income of 15 cents per share. Earnings, adjusted for non-recurring costs, were 20 cents per share. The drug developer posted revenue of $64.8 million ...
- ACCESSWIRE•2 months ago
CLASS ACTION UPDATE for CORT, NIO and BSX: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
NEW YORK, NY / ACCESSWIRE / May 9, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested ...
- GlobeNewswire•2 months ago
Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Corcept Therapeutics Incorporated
Law Offices of Howard G. Smith reminds investors of the upcoming May 13, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Corcept Therapeutics Incorporated (“Corcept” or the “Company”) (NASDAQ: CORT) securities between August 2, 2017 and February 5, 2019, inclusive (the “Class Period”). Investors suffering losses on their Corcept investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com.
- GlobeNewswire•2 months ago
Corcept Therapeutics Announces First Quarter 2019 Financial Results and Provides Corporate Update
MENLO PARK, Calif., May 09, 2019 -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat.
